BCL2 and hematologic disorder: Venetoclax is an anti-BCL2 agent approved in Europe for the treatment of chronic lymphocytic leukemia (CLL) that has shown therapeutic activity in mantle cell lymphoma (MCL) and other hematological malignancies (15–17).